ProEncia Biotechnology Closes Pre-Seed Funding

The company plans to use the funding to develop, further commercialize, and license a range of new non-invasive periodontal care products for patients with periodontal disease at all stages of severity.

The company announced that the U.S. Patent and Trademark Office has confirmed its provisional patent application (No. 63/765,225), titled “Compositions and Method for Prophylactic, Symptomatic, Therapeutic, and Cosmetic Periodontal Care,” has been converted into a non-provisional PCT international application (No. 19/548,447) and entered into the federal patent filing system.

“According to the World Health Organization, more than one billion people globally, and more than 100 million people in the U.S., suffer from periodontal disease,” said Tapos Ghosh, CEO and Co-Founder, ProEncia Biotechnology. “There’s an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition.”

Read More:Commure Raises $70M in Funding Led by General Catalyst

“The commercial demand for a new approach to periodontal treatment is enormous,” said Austin Loeb, COO and Co-Founder, ProEncia Biotechnology. “The ProEncia team is committed to advancing its groundbreaking treatment and expanding care options for periodontal disease patients.”

About ProEncia Biotechnology

Founded by Tapos G. and Austin Loeb, ProEncia Biotechnology is a Minnesota-based oral care company focused on developing easy-to-use, non-toxic, non-invasive treatments for periodontal disease at all stages, including gingivitis and periodontitis. The company’s products are built on novel, patent-pending technology and include both preventive and therapeutic solutions.

Read More:Century Health Raises $5M in Seed Funding Led by Origin Ventures